



**Assoc. Prof. Roger Allison**  
Executive Director  
Cancer Care Services



**Adj. Assoc. Prof. Alanna Geary**  
Nursing Director  
Cancer Care Services

## Overview

Research plays a critical role in the discovery and clinical development of new cancer treatments. Researchers from our service line are involved at every stage of the process from discovery of molecules to researching the best supportive care for patients receiving treatment.

Cancer Care Services at Royal Brisbane and Women's Hospital plays a key role at a state and national level.

We cover a large geographic area from Longreach to northern New South Wales, as well as our large metropolitan population. The degree of specialisation of our teams allows large numbers of patients to be offered involvement in clinical trials – from small investigator initiated trials to large international co-operative group trials. The increasing number of trials available attests to the increasing sophistication of treatment approaches and the dedication of our researchers.

Research, education and patient care underpin good multidisciplinary care. We undertake research into some of the newest technologies whilst appreciating that we have a duty to maximise the benefit for health dollars expended.

In presenting this report we thank our many collaborators, donors and patients who have made this possible.

## Key departments

- » Clinical Haematology and Bone Marrow Transplant Research Unit
- » Department of Medical Oncology
- » Department of Radiation Oncology
- » Queensland Haemophilia Centre

## Executive and directing staff

**Assoc. Prof. Roger Allison**  
Executive Director, Cancer Care Services

**Adj. Assoc. Prof. Alanna Geary**  
Nursing Director, Cancer Care Services

**Assoc. Prof. Simon Durrant**  
Director, Clinical Haematology and Bone Marrow Transplant

**Dr David Wyld**  
Director, Medical Oncology

**Assoc. Prof. Graeme Dickie**  
Director, Radiation Oncology

**Dr John Rowell**  
Director, Haematology

# Clinical Haematology and Bone Marrow Transplant Research Unit



**Assoc. Prof. Simon Durrant**  
Director, Clinical Haematology  
and Bone Marrow Transplant

## Overview

The Clinical Haematology and Bone Marrow Transplant Research Unit provides an exceptional research program for complex blood disorders including leukaemia, lymphoma and myeloma.

The unit is the Clinical Haematology Referral Centre for central Queensland, the Bone Marrow Transplant Referral Centre for Queensland and is the first bone marrow transplant unit in Australia to hold accreditation from the Foundation for the Accreditation of Cellular Therapy.

In addition to clinical haematology treatment, the unit provides:

- » Autologous stem cell transplants
- » Allogeneic stem cell and bone marrow transplants – related and unrelated
- » Clinical trials (both in-house and pharmaceutical-sponsored) for haematology and transplant patients.

The unit conducts a wide range of innovative trials, Phase I to Phase IV, into haematological malignancies. These trials include the testing of new therapeutic agents for the treatment of leukaemia, lymphoma and myeloma as well as improvements in the outcome of bone marrow transplantation.

The unit's active research program includes a variety of local investigator-driven and research facility studies, collaborative study group participation and participation in sponsored international studies.

There is an ongoing and strengthened collaboration between departmental clinical staff and the Queensland Institute of Medical Research, which corresponds to an improved ability to develop and participate in translational research programs.

Ongoing development of a national reference centre of excellence for cellular therapy of leukaemia and managing the adverse affects associated with stem cell transplant is continuing.

The program actively contributes bone marrow transplant outcome data to National and International Blood and Marrow Transplant Registries and maintains a bone marrow transplant specific database.

The Clinical Haematology and Bone Marrow Transplant Research Unit is committed to expanding the understanding of adult blood disorders and improving strategies for its management and treatment.

## Research staff

Name	Qualifications	Position	Interests/specialties
Assoc. Prof. Simon Durrant	MRCS, LRCP, MBBS, FRCP, FRCPATH	Director, Clinical Haematology and Bone Marrow Transplant; Assoc. Prof. Medicine, UQ	clinical haematology, bone marrow transplant
Assoc. Prof. Glen Kennedy	MBBS (Hons), FRACP, FRCPA	Deputy Director, Clinical Haematology and Bone Marrow Transplant	clinical haematology, bone marrow transplant
Prof. Andrew Boyd	BMedSc, MBBS, Ph.D, FRACP	Consultant Haematologist; Assistant Director and Senior Principal Research Fellow, QIMR; Professor, Experimental Haematology, UQ	clinical haematology, bone marrow transplant
Dr Ann Gillett	MBBS, FRACP, FRCPA	Consultant Haematologist	clinical haematology
Prof. Geoff Hill	BHB, MBChB, FRACP, FRCPA, MD	Clinical Haematology and Bone Marrow Transplant Staff Specialist	QIMR
Dr James Morton	Master of Medical Science (Epidemiology), MBBS, FRACP, FRCPA (Haematology)	Clinical Haematology and Bone Marrow Transplant Staff Specialist	clinical haematology, bone marrow transplant
Dr Jason Butler	MBBS, FRACP, FRCPA, M.Med.Sci (Clin Epid)(Newcastle)	Clinical Haematology and Bone Marrow Transplant Staff Specialist	clinical haematology, bone marrow transplant
Dr Kirk Morris	MBBS, FRACP, FRCPA	Senior Medical Officer, Clinical and Laboratory Haematology	clinical haematology
Dr Siok Tey	MBBS, FRACP, FRCPA (Clinical Haematology and Haematopathology)	Clinical Haematology and Bone Marrow Transplant Staff Specialist; Senior Lecturer, School of Medicine, UQ	clinical haematology, bone marrow transplant
Dr Ashish Misra	MBBS, FRACP, FRCPA	Clinical Haematology and Bone Marrow Transplant Staff Specialist	clinical haematology, bone marrow transplant

## Research staff

Name	Qualifications	Position	Interests/specialties
Dr Elango Subramonia Pillai	MBBS, FRACP, FRCPA	Consultant Haematologist; Clinical Haematology and Bone Marrow Transplant Staff Specialist	clinical haematology, bone marrow transplant
Dr Steven Lane	MBBS, FRACP, FRCPA, FRCP, RCPA	Clinical Haematologist; Senior Research Officer, QIMR	clinical haematology, bone marrow transplant
Dr Cameron Curley	MBBS, FRACP, FRCPA	Clinical Haematology and Bone Marrow Transplant Staff Specialist	clinical haematology, bone marrow transplant

## Supervised post-graduate students

Name	Current studies	Research topic
Vu, T.	PhD	Epigenetics in AML

## Awards and achievements

Award	Event	Name
Ralph Doherty Science Prize, QIMR		Boyd, A.

## Research grants

Investigators	Research title	Granting body	Amount awarded	Years of funding
Boyd, A.W., Reynolds, B.	EphA3 is a marker of glioma stem/progenitor cells and a potential target for therapy	NHMRC	\$560,000	2012-2014
Piper, M., Richards, L., Boyd, A.W., Bailey, T.	Nfib regulates glial differentiation during development and disease via repression of the key epigenetic protein, Ezh2	NHMRC	\$553,650	2012-2014
S Rose, S., Boyd, A.W., Fisk, N., Thomas, P.	The development of innovative multiplexed molecular imaging technology targeting improved diagnostic imaging of Glioblastoma Multiforme	NHMRC	\$389,910	2012-2014
Johns, T., Boyd, A.W., McDonald, K.	An integrated systems biology approach for the development of new therapeutic strategies for the treatment of high grade glioma	NHMRC	\$673,500	2012-2014
Khanna, R., Hill, G.R., Tey, S.K.	Developing personalised immunotherapies	QIMR Ride To Conquer Cancer Flagship Grant	\$1,200,000	2012-2015
Lane, S.	Targeting leukaemia stem cells to cure AML	Rhys Pengelly Fellowship in Leukaemia Research	\$450,000	2011-2014
Lane, S.	Treatment of blood diseases by targeting the disease-causing stem cells	Leukaemia Foundation of Australia/Cure Cancer Foundation Postdoctoral Fellowship	\$300,000	2011-2014
Lane, S.	Targeting human stem cells in JAK2 V617F position MPN	Leukaemia Foundation of Australia	\$100,000	2012-2014
Lane, S.	Targeting leukaemia stem cells in myeloproliferative neoplasms	NHMRC	\$451,000	2012-2014
Lane, S.	A novel human xenograft system to validate leukaemia stem cell function in vivo	Rio Tinto Ride to Conquer Cancer Project Grant	\$55,000	2012-2012

## Publications

- Agarwal S, O'Donoghue S, Gowardman J, Kennedy G, Bandeshe H, Boots R. Intensive care unit experience of hematopoietic stem cell transplant patients: *Internal Medicine Journal*. 2012;42(7):748-754.
- Bensing W, Maziarz RT, Jagannath S, Spencer A, Durrant S, Becker PS, Ewald B, Bilic S, Rediske J, Baeck J, Stadtmauer EA. A phase I study of lucatumumab, a fully human anti-CD40 antagonist monoclonal antibody administered intravenously to patients with relapsed or refractory multiple myeloma. *British J Haematology*. 2012;59:58-66.
- Coulthard MG, Morgan M, Woodruff TM, Arumugam TV, Taylor SM, Carpenter TC, Lackmann M, Boyd AW. Eph/Ephrin signaling in injury and inflammation. *Am J Pathol*. 2012;181(5):1493-503.
- Curley C, Pillai E, Mudie K, Western R, Hutchins C, Durrant S, Kennedy GA. Outcomes after major or bidirectional ABO-mismatched allogeneic hematopoietic progenitor cell transplantation after pretransplant isoagglutinin reduction with donor-type secretor plasma with or without plasma exchange. *Transfusion*. 2012;52:291-297.
- de Bock CE, Ardjmand A, Molloy TJ, Bone SM, Johnstone D, Campbell DM, Shipman KL, Yeadon TM, Holst J, Spanevello MD, Nemes G, Catchpoole DR, Lincz LF, Boyd AW, Burns GF, Thorne RF. The Fat1 cadherin is overexpressed and an independent prognostic factor for survival in paired diagnosis-relapse samples of precursor B-cell acute lymphoblastic leukemia. *Leukemia*. 2012;26:918-926.
- Dixon KJ, Munro KM, Boyd AW, Bartlett PF, Turnley AM. Partial change in EphA4 knockout mouse phenotype: loss of diminished GFAP upregulation following spinal cord injury. *Neurosci Lett*. 2012;525(1):66-71.
- Garizio DG, Wilgen U, Williams B, Kennedy GA. Clinical utility of ADAMTS-13 testing in suspected thrombotic microangiopathy (TMA): an audit of ADAMTS-13 activity assay requests in routine practice from a tertiary hospital. *Pathology*. 2012;44(7):638-641.
- Heidel FH, Bullinger L, Feng Z, Wang Z, Neff TA, Stein L, Kalaitzidis D, Lane SW. Genetic and pharmacologic inhibition of  $\beta$ -catenin targets imatinib-resistant leukemia stem cells in CML. *Armstrong SA. Cell Stem Cell*. 2012;10(4): 412-24.
- Jagasia MH, Abonour R, Long GD, Bolwell BJ, Laport GG, Shore TB, Durrant S, Szer J, Chen M-G, Lizambri R, Waller EK. Palifermin for the reduction of acute GVHD: a randomised, double-blind, placebo-controlled trial. *Bone Marrow Transplantation*. 2012;47:1350-1355.
- Kalaitzidis D, Sykes SM, Wang Z, Punt N, Tang Y, Ragu C, Sinha AU, Lane SW, Souza AL, Clish CB, Anastasiou D, Gilliland DG, Scadden DT, Guertin DA, Armstrong SA. mTOR complex 1 plays critical roles in hematopoiesis and Pten-loss-evoked leukemogenesis. *Cell Stem Cell*. 2012;11(3):429-39.
- Lane SW. Bad to the Bone. *Blood*. 2012;119(2):323-5.
- Lane SW, De Vita S, Alexander KA, Karaman R, Milsom MD, Dorrance AM, Purdon A, Louis L, Boussein ML, Williams DA. Rac signaling in osteoblastic cells is required for normal bone development but is dispensable for hematopoietic development. *Blood*. 2012;119(3):736-44.
- Lane SW, Gill D, McMillan NA, Saunders N, Murphy R, Spurr T, Keane C, Fan HM, Mollee P. Valproic acid combined with cytosine arabinoside in elderly patients with acute myeloid leukemia has in vitro but limited clinical activity. *Leuk Lymphoma*. 2012;53(6):1077-83.
- Mullally A, Lane SW, Brumme K, Ebert BL. Myeloproliferative neoplasm animal models. *Hematol Oncol Clin North Am*. 2012;26(5): 1065-81.
- Mullally A, Poveromo L, Schneider RK, Al-Shahrour F, Lane SW, Ebert BL. Distinct roles for long-term hematopoietic stem cells and erythroid precursor cells in a murine model of Jak2V617F-mediated polycythemia vera. *Blood*. 2012;120(1):166-72.
- Robb R and Hill GR. The interferon dependent orchestration of innate and adaptive immunity after transplantation. *Blood*. 2012; 119:5351-8.
- Smith C, Elhassen D, Gras S, Wynn KK, Dasari V, Tellam J, Tey SK, Rehan S, Liu YC, Rossjohn J, Burrows SR, Khanna R. Endogenous antigen presentation impacts on T-box transcription factor expression and functional maturation of CD8+ T cells. *Blood*. 2012;120(16):3237-45.
- Serody J and Hill GR. The IL-17 differentiation and its role in transplant outcome. *Biol Blood Marrow Transplant*. 2012;18:S56-61.
- Tey SK, Khanna R. Host immune system strikes back: autophagy-mediated antigen presentation bypasses viral blockade of the classic MHC class I processing pathway. *Autophagy*. 2012;8(12):1839-41.

# Department of Medical Oncology



**Dr David Wyld**  
Director, Medical Oncology

## Overview

The Department of Medical Oncology provides clinical services to patients at RBWH and The Prince Charles Hospital (TPCH). It also acts as the major tertiary referral centre for the central zone, including providing outreach clinics to Rockhampton, Hervey Bay and Bundaberg.

The department has an ongoing, active clinical research program and is currently involved in approximately 70 Clinical Trials. These include RBWH specific investigator initiated studies, large international studies and studies conducted as part of Australian cooperative cancer-trials groups, (such as the ANZ Breast Cancer Trials Group, the ANZ Gastro-Intestinal Trials Group, the ANZ Lung Cancer Trials Group, The Australian and New Zealand Urogenital and Prostate cancer Trials group and the ANZ Gynaecology-Oncology Group).

The worth of our clinical trials program is acknowledged by the Queensland Cancer Fund, which provides funding for research staff on the basis of demonstrated accrual to approved, unfunded randomised Phase II and III studies.

Several clinical staff from the unit also have broader roles within Australasian collaborative cancer trials groups, including membership of executive committees, roles as Australian Principal Investigators for some national studies, positions on individual Australia-wide trial management committees and on trial data monitoring and safety committees.

There is ongoing collaboration between departmental clinical staff and other institutions such as the Queensland Institute of Medical Research (QIMR) and TPCP, improving the unit's ability to develop and participate in translational research programs.

Areas of specific interest include Dr Inglis' collaborative work in the area of neuro-oncology, Dr Hughes' ongoing collaboration related to pulmonary malignancies with Dr Fong at TPCH, Dr Burge's collaboration with Dr Leggett's laboratory regarding colorectal cancer, ongoing collaboration with the RBWH Department of Nuclear Medicine in areas including investigating the utility of PET imaging in staging of operable pancreatic cancer as well as ongoing work related to imaging and therapy for neuroendocrine tumours. Head and neck malignancies and gynaecological cancers remain areas of specific ongoing clinical research activity.

## Research staff

Name	Qualifications	Position	Interests/specialties
Dr David Wyld	MBBS (Hons), FRACP	Director Medical Oncology	gastro-intestinal, neuroendocrine
Dr Brett Hughes	BSc (Med), MBBS (Hons), FRACP	Staff Specialist	lung, mesothelioma, head and neck, thyroid
Assoc. Prof. Nicole McCarthy	MBBS (Hons), MHSc, FRACP	Staff Specialist	breast, gynaecology
Dr Geoffrey Beadle	MBBS, FRACP, FRACR	Staff Specialist	breast cancer
Dr Matthew Burge	MBChB, FRACP	Staff Specialist	gastro-intestinal, phase I studies
Dr Melissa Eastgate	MBBS, FRACP	Staff Specialist	gastro-intestinal, melanoma, head and neck cancer
Dr Michelle Nottage,	MBChB, FRACP	Staff Specialist	breast, head and neck cancers
Dr Rick Abraham	MBBS, MMedSc, FRACP	Staff Specialist	lung, urology, breast cancer
Dr Po-Ling Inglis	BSc (Molecular Biology), MBBS, FRACP	Staff Specialist	breast, lung, central nervous system
Dr Jeffrey Goh,	MBBS, FRACP	Staff Specialist	gynaecology, central nervous system
Dr Alison Hadley	MBBS (Hons), MMed (Clin Epi), FRACP	Staff Specialist	gynaecology, breast, gastro-intestinal cancer
Dr Amit Sharma	MBBS, MRCP, FRACP	Medical Oncology Fellow	
Annette Cubitt	RN, Grad Cert (Clinical Trials Management), CCRP	Clinical Trials Manager	
Jenny Campbell	RN, BSc (Nursing)	Clinical Trial Coordinator	

## Research staff

Name	Qualifications	Position	Interests/specialties
Andrea McKenzie	EEN	Clinical Trial Coordinator	
Dianna Lewis	BSc (Nursing), GradCert (Cancer Nursing)	Clinical Trial Coordinator	
Jo-Ann Horn	RN	Clinical Trial Coordinator	
Natasha Roberts	BN (Hons)	Clinical Trial Coordinator	
Amy Ives	BN AssocSc N	Clinical Trial Coordinator	
David Hickey	BAppSc	Clinical Trial Coordinator	
Victoria Holt	BA (Hons), Grad Dip Lib Stud	Research Assistant	

## Research grants

Investigators	Research title	Granting body	Amount awarded	Years of funding
Department of Medical Oncology	Cancer Clinical Trial Data Management Grant	Queensland Cooperative Oncology Group	48,000.00	2012
Inglis, P., QIMR, QBI, RBWH	QIMR/QBI/RBWH Brain tumour and Cell Culture Bank	RBWH Private Practice Trust Fund	\$92,000.00	2011-2012
Inglis, P., TPCH, RBWH	Familial lung cancer discovering genes for inherited lung cancer	TPCH Foundation	\$10,000.00	2012
Hughes, B.	Improving quality of life in high-risk cancer populations: A randomised trial of a structured intervention for head and neck cancer survivors	NHMRC	\$476,074.46	2012
Hughes, B.	Detection of treatment-responsive lung cancer mutations	TPCH Foundation	\$94,515	2012

## Publications

Alexandre J, Brown C, Coeffic D, Raban N, Pfisterer J, Mäenpää J, Chalchal H, Fitzharris B, Volgger B, Vergote I, Pisano C, Ferrero A, Pujade-Lauraine E. CA-125 can be part of the tumour evaluation criteria in ovarian cancer trials: Experience of the GCIG CALYPSO trial. *Br J Cancer*. 2012;Feb 14;106(4):633-7 (RBWH HREC Protocol 2005/058) McCarthy NM, Goh J.

Brown TE, Spurgin AL, Ross L, Tripcony L, Keller J, Hughes BG, Hodge R, Walker Q, Banks M, Kenny LM, Crombie J. Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy. *Head Neck*. 2012; Sep 13 doi: 10.1002/hed.23146. [Epub ahead of print] Hughes BG.

Brundage M, Gropp M, Mefti F, Mann K, Lund B, GebSKI V, Wolfram G, Reed N, Pignata S, Ferrero A, Brown C, Eisenhauer E, Pujade-Lauraine E. Health-related quality of life in recurrent platinum-sensitive ovarian cancer: Results from the CALYPSO trial. *Ann Oncol*. 2012;Aug;23(8):2020-7 (RBWH HREC Protocol 2005/058) McCarthy NM, Goh J.

Burge M, Islam MF, Morris K, Windsor M, Perry-Keene J, Curley C. Successful treatment of a primary mediastinal germ cell tumour complicated by hemophagocytic syndrome. *Asia Pac J Clin Oncol*. 2012 Dec;8(4):e97-8. Burge M.

Chan RJ, Alexander A, Bransdon M, Webster J, Hughes BG, Brown L, Graham T. Challenging the distal-to-proximal cannulation technique for administration of anticancer therapies: a prospective cohort study. *Cancer Nurs*. 2012;Sep-Oct;35(5):E35-40 (HREC/09/QRBW/72) Hughes BG.

Chirgwin J, Sun Z, Smith I, Price KN, Thürlimann B, Ejlersen B, Bonnefoi H, Regan MM, Goldhirsch A, Coates AS; BIG 1-98 Collaborative and International Breast Cancer Study Groups. The advantage of letrozole over tamoxifen in the BIG 1-98 trial is consistent in younger postmenopausal women and in those with chemotherapy-induced menopause. *Breast Cancer Res Treat*. 2012 Jan;131(1):295-306. (RBWH HREC Protocol 2001/067) McCarthy NM, Beadle G.

Ewertz M, Gray KP, Regan MM, Ejlersen B, Price KN, Thürlimann B, Bonnefoi H, Forbes JF, Paridaens RJ, Rabaglio M, Gelber RD, Colleoni M, Láng I, Smith IE, Coates AS, Goldhirsch A, Mouridsen HT. Obesity and risk of recurrence or death after adjuvant endocrine therapy with letrozole or tamoxifen in the Breast International Group 1-98 trial. *J Clin Oncol*. 2012;Nov 10;30(32):3967-75 (RBWH HREC Protocol 2001/067) McCarthy NM, Beadle G.

## Publications

- Fernandez-Cuesta L, Oakman C, Falagan-Lotsch P, Smoth K, Quinaux E, Buyse M, Dolci MS, De Azambuja E, Hainaut P, Dell'Orto P, Larsimont D, Francis PA, Crown J, Piccart-Gebhart M, Viale G, Di Leo A, Olivier M. Prognostic and predictive value of TP53 mutations in node-positive breast cancer patients treated with anthracycline- or anthracycline/taxane based adjuvant therapy: Results from the BIG 02-98 phase III trial. *Breast Cancer Res.* 2012;May 2;14(3):R70 (RBWH HREC Protocol 1999/69) Wyld D.
- Fizazi K, Scher HI, Molina A, Logothetis CJ, Chi KN, Jones RJ, Staffurth JN, North S, Vogelzang NJ, Saad F, Mainwaring P, Harland S, Goodman OB Jr, Sternberg CN, Li JH, Kheoh T, Haqq CM, de Bono JS Abiraterone acetate for treatment of metastatic castration-resistant prostate cancer: final overall survival analysis of the COU-AA-301 randomised, double-blind, placebo-controlled phase 3 study. *Lancet Oncol.* 2012;Oct;13(10):983-92 (RBWH HREC Protocol 2008/028) Nottage M, Inglis PL.
- Gladiëff L, Ferrero A, De Rauglaudre G, Brown C, Vasey P, Reinthaller A, Pujade-Lauraine E, Reed N, Lorusso D, Siena S, Helland H, Elit L, Mahner S. Carboplatin and pegylated liposomal doxorubicin versus carboplatin and paclitaxel in partially platinum-sensitive ovarian cancer patients: Results from a subset analysis of the CALYPSO phase III trial. *Ann Oncol.* 2012 May;23(5):1185-9 (RBWH HREC Protocol 2005/058) McCarthy NM, Goh J.
- Goldstein D, Spry N, Cummins MM, Brown C, van Hazel GA, Carroll S, Selva-Nayagam S, Borg M, Ackland SP, Wratten C, Shapiro J, Porter IW, Hruby G, Horvath L, Bydder S, Underhill C, Harvey J, GebSKI VJ. Australasian Gastro-Intestinal Trials Group. The GOFURTGO Study: AGITG phase II study of fixed dose rate gemcitabine-oxaliplatin integrated with concomitant 5FU and 3D conformal radiotherapy for the treatment of localised pancreatic cancer. *Br J Cancer.* 2012;Jan 3;106(1):61-9 (RBWH HREC Protocol 2005/096) Eastgate M.
- Kirchhoff T, Gaudet MM, Antoniou AC, et al, Breast cancer risk and 6q22.33: combined results from Breast Cancer Association Consortium and Consortium of Investigators on Modifiers of BRCA1/2. *PLoS One.* 2012;7(6):e35706. doi: 10.1371/journal.pone.0035706. Epub 2012 Jun 29 (This publication is electronic only.) Wyld D.
- Neoptolemos JP, Moore MJ, Cox TF, Valle JW, Palmer DH, McDonald AC, Carter R, Tebbutt NC, Dervenis C, Smith D, Glimelius B, Charnley RM, Lacaine F, Scarfe AG, Middleton MR, Anthony A, Ghaneh P, Halloran CM, Lerch MM, Oláh A, Rawcliffe CL, Verbeke CS, Campbell F, Büchler MW, European Study Group for Pancreatic Cancer. Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: The ESPAC-3 periampullary cancer randomised trial. *JAMA.* 2012;Jul 11;308(2):147-56 (RBWH HREC Protocol 2004/047) Wyld D.
- Peate M, Meiser B, Cheah BC, Saunders C, Butow P, Thewes B, Hart R, Phillips KA, Hickey M, Friedlander M. Making hard choices easier: A prospective, multi-centre study to assess the efficacy of a fertility-related decision aid in young women with early-stage breast cancer. *Br J Cancer.* 2012;Mar 13;106(6):1053-61 (RBWH HREC Protocol 2006/029) McCarthy NM.
- Punnoose EA, Atwal S, Liu W, Raja R, Fine BM, Hughes BG, Hicks RJ, Hampton GM, Amler LC, Pirzkall A, Lackner MR. Evaluation of circulating tumor cells and circulating tumor DNA in non-small cell lung cancer: Association with clinical endpoints in a Phase II Clinical Trial of Pertuzumab and Erlotinib. *Clin Cancer Res.* 2012;Apr 15;18(8):2391-401 (RBWH HREC Protocol 2008/019). Hughes BG.
- Price TJ, Zannino D, Wilson K, Simes J, Cassidy J, Van Hazel GA, Robinson BA, Broad A, Ganju V, Ackland SP, Tebbutt NC. Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: A subgroup analysis from the AGITG MAX trial: An international, randomised, controlled trial of capecitabine, bevacizumab and mitomycin C. *Annals of Oncology.* 2012;23(6):1353–1536 (RBWH HREC Protocol 2005/076) Wyld D.
- Regan MM, Leyland-Jones B, Bouzyk M, Pagani O, Tang W, Kammler R, Dell'orto P, Biasi MO, Thürlimann B, Lyng MB, Ditzel HJ, Neven P, Debled M, Maibach R, Price KN, Gelber RD, Coates AS, Goldhirsch A, Rae JM, Viale G, Breast International Group (BIG) 1-98 Collaborative Group. CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: The Breast International Group 1-98 Trial. *J Natl Cancer Inst.* 2012;104(6):441-451. (RBWH HREC Protocol 2001/067) McCarthy NM, Beadle G.
- Ribi K, Aldridge J, Phillips KA, Thompson A, Harvey V, Thürlimann B, Cardoso F, Pagani O, Coates AS, Goldhirsch A, Price KN, Gelber RD, Bernhard J, BIG 1-98 Collaborative Group, International Breast Cancer Study Group. Subjective cognitive complaints one year after ceasing adjuvant endocrine therapy for early stage breast cancer. *Br J Cancer.* 2012 May 8;106(10):1618-25. (RBWH HREC Protocol 2001/067) McCarthy NM, Beadle G.
- Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Fléchon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS. Increased survival with enzalutamide in prostate cancer after chemotherapy. *N Engl J Med.* 2012;Sep 27;367(13):1187-97. Nottage M.
- Schmoll HJ, Cunningham D, Sobrero A, Karapetis CS, Rougier P, Koski SL, Kocakova I, Bondarenko I, Bodoky G, Mainwaring P, Salazar R, Barker P, Mookerjee B, Robertson J, Van Cutsem E. Cediranib with mFOLFOX6 versus bevacizumab with mFOLFOX6 as first-line treatment for patients with advanced colorectal cancer: a double-blind, randomised phase III study (HORIZON III). *J Clin Oncol.* 2012 Oct 10;30(29):3588-95 (RBWH HREC Protocol 2006/102) Wyld D.
- So WK, Chan RJ, Chan DN, Hughes BG, Chair SY, Choi KC, Chan CW. Quality-of-life among head and neck cancer survivors at one year after treatment--a systematic review. *Eur J Cancer.* 2012;Oct;48(15):2391-408.
- Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, Rougier P, Bechstein WO, Primrose JN, Walpole ET, Finch-Jones M, Jaeck D, Mirza D, Parks RW, Collette L, Van Cutsem E, Scheithauer W, Lutz MP, Nordlinger B, EORTC Gastro-Intestinal Tract Cancer Group, Cancer Research UK (CRUK), Arbeitsgruppe Lebermetastasen und-tumoren in der Chirurgischen Arbeitsgemeinschaft Onkologie (ALM-CAO), Australasian Gastro-Intestinal Trials Group (AGITG), Fédération Francophone de Cancérologie Digestive (FFCD). Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). *Annals of Surgery.* 2012;255(3):534–539 (RBWH HREC Protocol 2001/035) Wyld D.

---

## Publications

Sultana A, Cox T, Ghaneh P, Neoptolemos JP. Adjuvant therapy for pancreatic cancer. *Recent Results Cancer Res.* 2012;196:65-88 (RBWH HREC Protocol 2001/035 and 2004/047) Wyld D.

Wagner U, Marth C, Largillier R, Kaern J, Brown C, Heywood M, Bonaventura T, Vergote I, Piccirillo MC, Fossati R, GebSKI V, Lauraine EP. Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients. *Br J Cancer.* 2012;Aug 7;107(4):588-91 (RBWH HREC Protocol 2005/058) McCarthy NM, Goh J.

Wylie N, Adib R, Barbour AP, Fawcett J, Hill A, Lynch S, Martin I, O'Rourke TR, Puhalla H, Rutherford L, Slater K, Whiteman DC, Neale RE, Queensland Pancreatic Cancer Study Group. Surgical management in patients with pancreatic cancer: A Queensland perspective. *ANZ J Surg.* 2012;Oct 24;1445-2197. Burge M.

Zaman K, Thürlimann B, Huober J, Schönenberger A, Pagani O, Lüthi J, Simcock M, Giobbie-Hurder A, Berthod G, Genton C, Brauchli P, Aebi S, Swiss Group for Clinical Cancer Research (SAKK). Bone mineral density in breast cancer patients treated with adjuvant letrozole, tamoxifen, or sequences of letrozole and tamoxifen in the BIG 1-98 study (SAKK 21/07) *Ann Oncol.* 2012;Jun;23(6):1474-81 (RBWH HREC Protocol 2001/067) McCarthy NM, Beadle G.



# Department of Radiation Oncology



**Assoc. Prof. Graeme Dickie**  
Director, Radiation Oncology

## Overview

The Department of Radiation Oncology provides radiotherapy services to a wide geographic area with treatment being delivered at the Royal Brisbane and Women's Hospital.

The department provides service to the Royal Children's Hospital (RCH) as well as outreach to the Prince Charles, Rockhampton, Longreach, Hervey Bay, Maryborough, Bundaberg, Redcliffe and Caboolture Hospitals. The unit is fortunate to be the first Australian site to have helical TomoTherapy available.

It has been a productive year for cancer research in Radiation Oncology at RBWH. Our core clinical research activity continues in concert with the busy clinical department.

We are grateful for our donors who continue to make funds available to support our work. We are particularly proud of our success in highly competitive National Health and Medical Research Council (NHMRC) and Australian Cancer Research Foundation (ACRF) grants.

Over the last few years the trials program has progressed from largely retrospective investigator initiated trials to more translational and prospective projects.

Physics research has assumed a greater profile and we have a number of investigator initiated projects. Our new computing cluster has dramatically improved computation time and accelerated this work. Advanced imaging remains central to these technologies. This underlines the importance of an active imaging and medical physics research program.

We look forward to further interaction with our collaborators at Queensland Institute of Medical Research (QIMR), Queensland University of Technology (QUT), The University of Queensland Centre for Clinical Research (UQCCR) and the Queensland PET centre. We thank our collaborators and especially the many patients who have given their time to be involved in clinical trials.

## Research staff

Name	Qualifications	Position	Interests/specialties
Assoc. Prof. Graeme Dickie	MBBS, MBA, FRACP, FRANZCR	Director, Radiation Oncology	radiation oncology
Assoc. Prof. Roger Allison	MBBS, MRCP, FRCR, FRANZCR, FACHPM	Staff Specialist	radiation oncology, paediatric
Dr Philip Chan	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Robyn Cheuk	MBBS (SA), DRACR	Staff Specialist	radiation oncology, paediatric
Dr Michael Fay	MBChB, FRACP, FRANZCR	Director, Research	radiation oncology, brain tumours
Dr Michelle Grogan	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Lizbeth Kenny	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Charles Lin	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Gary Pratt	MBBS, FRANZCR	Staff Specialist	radiation oncology
Dr Sue Whitaker	MBChB, DMRT, FRCR, FRANZCR	Staff Specialist	radiation oncology
Lee Tripcony	BSc	Principal Clinical Scientist Statistics	database, statistics
Jacqui Keller	BBus (HIM)	Manager Clinical Trials	research, clinical trials
Jennifer Edmunds	RN, BHSc	Clinical Trial Coordinator	research, clinical trials
Rebecca Pincus	RN, BN, GradCertCDM	Clinical Trial Coordinator	research, clinical trials
Charmaine Mickelwright		Research Assistant	research, clinical trials
Greg Rattray	BAppSc (MRT), GradCertHMgt, FIR	Director, Radiation Therapy	radiation therapy
Daniel Bryant	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Kurt Burrows	BAppSc (RT)	Radiation Therapist	radiation therapy
Adrian Celati	BAppSc (RT)	Radiation Therapist	radiation therapy
Kevina Chroma	MHSc, MRS, GradDipHMgt	Radiation Therapist (Advanced)	radiation therapy
Stacey Cooke	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy

## Research staff

Name	Qualifications	Position	Interests/specialties
Jemma Devereaux	BAppSc (RT)	Radiation Therapist	radiation therapy
Shayne Etherton	BAppSc (RT)	Radiation Therapist	radiation therapy
Selina Harris	BAppSc (RT)	Radiation Therapist	radiation therapy
Rob McDowall	GradCertHMgt, DipAppScRT	Senior Radiation Therapist (Planning)	radiation therapy
Janine Miles	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Julie-Anne Outhwaite	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Anthony Pagidas	BAppSc (RT)	Radiation Therapist	radiation therapy
Michelle Ralston	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Kathy Vidler	Dip.App Sc RT	Radiation Therapist	radiation therapy
Christopher Walsh	BAppSc (RT)	Radiation Therapist (Advanced)	radiation therapy
Darren Cassidy	BSc (Hons)	A/Director, Therapeutic Physics	medical physics
Robert Fitchew	BSc (Hons), MSc	Deputy Director, Medical Physics	medical physics
Phil Back	BSc, MSc, PhD	Physicist - Advanced	medical physics
Alastair Dick	BSc, MSc	A/Principal Physicist, Treatment Planning and Dosimetry	medical physics
Zoe Baldwin	BMRP	A/Physicist (Senior)	medical physics
Onno Kamst	BSc, MSc, GradDipEd	Physicist (Advanced)	medical physics
Craig Lancaster	BSc, Grad Dip Med Phys	Senior Physicist	medical physics
Tim Markwell	BIT, BAppSc (Physics), MSc	Physicist Oncology Treatment	medical physics
Sanna Nilsson	BSc, MSc	Senior Physicist	medical physics
Christopher Poole	BEng, MSc, PhD	Medical Physicist, Research	medical physics
Steven Sylvander	BSc, MSc, PhD	Physicist (Advanced)	medical physics

## Supervised post-graduate students

Name	Current studies	Research topic
Baldwin, Z.	Masters (Research)	Commissioning of total body irradiation on oncentra masterplan
Burrows, K.	Masters (Research)	Optimisation of cranial immobilisation in patients with brain cancer treated on TomoTherapy
Kamst, O.	PhD	Portal dosimetry optimisation
Markwell, T.	PhD	Mega-voltage cone-beam CT
Outhwaite, J.	PhD	Head and neck immobilisation and adaptive dosimetry for variation in patient contour during treatment
Poole, C.	PhD	Faster monte carlo simulation of radiotherapy geometries

## Awards and achievements

Award	Event	Name
2012 Kenneth Clarke Journal Prize, Council of the Australian College of Physical Scientists and Engineers in Medicine Award for the best paper in Australasian Physical and Engineering Sciences in Medicine (Volume 34)		Poole, C.
Best Physicist in Exam Series, Council of the Australian College of Physical Scientists and Engineers in Medicine for the Best Physicist in Exam Series		Baldwin, Z.

## Research grants

Investigators	Research title	Granting body	Amount awarded	Years of funding
Rose, S., Kenny, L., Fay, M., Fisk, N. et al.	Australian Cancer Research Foundation Molecular Oncology Translational Imaging Facility	Australian Cancer Research Foundation	\$2,000,000	2012
Schofield, P., Aranda, S., Juraskova, I., Mileskin, L., Krishnasamy, M., White, K. (Cheuk, R-AI)	A nurse-led psychosocial intervention with peer support to reduce needs in women being treated with radiotherapy for gynaecological cancer: A RCT	NHMRC	\$1,133 \$411.80	2011-2014
Kneebone, A., Williams, S., Frydenberg, M., Duchesne, G., Fisher, R., Kenny, L.	RAVES: Radiotherapy adjuvant versus early salvage following radical prostatectomy	NHMRC	\$775,000	2009-2013
Rose, S., Crozier, S., Salvado, S., Coulthard, A., Thomas, P., Fay, M.	Improving the assessment of brain tumour treatment outcome using 18F-FDOPA PET – MRI fusion	NHMRC	\$637,125	2010-2013
Valery, P., Garvey, G., Fay, M., Martin, J., Baade, P.	Patterns of care, co-morbidities and quality of life in indigenous people with cancer	NHMRC	\$610,731	2011-2013
Rose, S., Boyd, A., Whittaker, A., Thomas, P., Fay, M., Fisk, N.	The development of innovative multiplexed molecular imaging technology targeting improved diagnostic imaging of Glioblastoma Multiforme	NHMRC	\$389,925	2012-2015
Dickie, GJ.	Cancer Council Queensland clinical trial data manager grant	Cancer Council Queensland	\$74,880	2012
Chan, P., Thomas, P.	Prognostic value of assessing hypoxia in tumours using FMISO OET during a course of radiation therapy –proof of concept study	RBWH Foundation	\$30,000	2012-2013
Fay, M.	Rotary Club – Rockhampton North	Rotary	\$24,000	2012
Fay, M., Markwell, T.	Low-cost, high-performance Monte Carlo cluster	RBWH Private Practice Trust Fund	\$8,500	2012
Bettington, C.	HREC/12/QRBW/129 A single-arm prospective study of the effect of preoperative chemoradiotherapy on sexual dysfunction in men with locally advanced rectal cancer	RANZCR Research Grant	\$10,000	2012-2016

## Publications

Brown TE, Spurgin AL, Ross L, Tripcony L, Keller J, Hughes BGM, Hodge R, Walker Q, Banks M, Kenny LM, Crombie J. Validated swallowing and nutrition guidelines for patients with head and neck cancer: Identification of high-risk patients for proactive gastrostomy. *Head and Neck*. Published on-line 13 September 2012

Buyyounouski M, Pickles T, Kestin L, Allison R, Williams S. Validating the interval to biochemical failure for the identification of potentially lethal prostate cancer. *J Clin Oncol*. 2012;30(15):1857-63.

Cartmill B, Cornwell P, Ward E, Davidson W, Nund R, Bettington C, Rahbari RM, Poulsen M, Porceddu S. Emerging understanding of dosimetric factors impacting on dysphagia and nutrition following radiotherapy for oropharyngeal cancer *Head Neck*. 2012 Jun 23. doi: 10.1002/hed.23040

Chan R, Keller J, Cheuk R, Blades R, Tripcony L, Keogh S. A double-blind randomised controlled trial of a natural oil-based emulsion (Moogoo Udder Cream®) containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer. *Radiation Oncology*. 2012;7:121.

Chan R, Larsen E, Chan P. Re-examining the evidence in Radiation Dermatitis Management Literature: An Overview and a Critical Appraisal of Systematic Reviews. *Int J Radiat Oncol Biol Phys*. 2012;Nov 1;84(3):e357-62.

Crombie AK, Farah C, Tripcony L, Dickie G, Batstone MD. Primary chemoradiotherapy for oral cavity squamous cell carcinoma. *Oral Oncol*. 2012;Oct;48(10):1014-8. doi: 10.1016/j.oraloncology.2012.03.027. Epub 2012 Apr 18.

Denham J, Wilcox C, Joseph D, Spry N, Lamb D, Tai K, Matthews J, Atkinson C, Turner S, Christie D, Gogna N, Kenny L, Duchesne G, Delahunt B, McElduff P. Quality of life in men with locally advanced prostate cancer treated with leuprorelin and radiotherapy with or without zoledronic acid (TROG 03.04 RADAR): Secondary endpoints from a randomised phase 3 factorial trial. *The Lancet Oncology*. 2012;13:1260-70.

## Publications

- Denham J, Wilcox C, Lamb D, Spry A, Duchesne G, Atkinson C, Matthews J, Turner S, Kenny L, Tai K, Gogna N, Ebert M, Delahunt B, McElduff P, Joseph D. Rectal and urinary dysfunction in the TROG 03.04 RADAR trial for locally advanced prostate cancer. *Radiotherapy and Oncology*. 2012;105(2):184-192.
- Fay M, Thomas P. Functional Imaging using PET and Radiotherapy Planning. *CancerForum*. Volume 36 Number 2 July 2012.
- Goergen SK, Pool FJ, Turner TJ, Grimm JE, Appleyard MN, Crock C, Fahey MC, Fay MF, Ferris NJ, Liew SM, Perry RD, Revell A, Russell GM, Wang SS, Wriedt C. Evidence-based guideline for the written radiology report: Methods, recommendations and implementation challenges. *Journal of Medical Imaging and Radiation Oncology*. Article first published online 28 DEC 2012 DOI: 10.1111/1754-9485.12014
- Graham P, Plant N, Graham J, Browne L, Martin Borg M, Capp A, Delaney GP, Harvey J, Kenny L, Francis M, Zissiadis Y. Digital photography as source documentation of skin toxicity: An analysis from the Trans Tasman Radiation Oncology Group (TROG) 04.01 Post-Mastectomy Radiation Skin Care Trial. *JMIR*. 2012;56(4):458-463.
- Hansen C, Kenny L, Lakhani S, Ung O, Keller J, Tripcony L, Cheuk R, Grogan M, Vargas A Vargas, Martin J. Tubular breast carcinoma: An argument against treatment de-escalation. *Journal of Medical Imaging and Radiation Oncology*. 2012;56;116–122.
- Hughes BGM, Jain VK, Brown T, Spurgin AL, Hartnett G, Keller J, Tripcony L, Appleyard M, Hodge R. Decreased hospital stay and significant cost savings after routine use of prophylactic gastrostomy for high-risk patients with head and neck cancer receiving chemoradiotherapy at a tertiary cancer institution. *Head and Neck*. 2013;Mar;35(3):436-42. doi: 10.1002/hed.22992. [Epub May 18 2012.]
- Kenny L. Interventional oncology: Can it walk the walk or will it just be all talk. Guest Editor - Royal College of Radiology Newsletter. December 2012.
- Lin C, Sia E, Keller J. Concurrent chemoradiation for T3 glottic squamous cell carcinoma: A reasonable alternative to upfront laryngectomy. Published at Volume 2012 (2012), Article ID 461217, *Advances in Cancer: Research Treatment*.
- Lin C, Tripcony L, Keller J, Poulsen M, Martin J, Jackson J, Dickie G. Perineural infiltration of cutaneous squamous cell carcinoma and basal cell carcinoma without clinical features. *Int J Radiat Oncol Biol Phys*. 2012; Jan 1;82:334-340.
- Outhwaite J, McDowall R, Marquart L, Rattray G, Fielding A, Hargrave C. Training program impact on thermoplastic immobilisation for head and neck radiation therapy. *Radiography*. 16 Sep 2012 1e7
- Poole CM, Cornelius I, Trapp JV, Langton CM. Fast Tessellated Solid Navigation in GEANT4. *Nuclear Science, IEEE Transactions on* 59.4. 2012:1695-1701.
- Poole CM, Cornelius I, Trapp JV, Langton CM. A CAD interface for GEANT4. *Australasian Physical and Engineering Science in Medicine*. 2012;1-6.
- Poole CM, Cornelius I, Trapp JV, Langton CM. Radiotherapy Monte Carlo simulation using cloud computing technology. *Australasian Physical and Engineering Sciences in Medicine*. 2012;35;4:497-502.
- Rose S, Fay M, Bourgeat P, Dowson N, Salvado O, Gai Y, Coulthard A, Crozier S. Correlation of MRI-derived apparent diffusion coefficients in newly diagnosed gliomas with [18F]-Fluoro-L-Dopa PET: What are we really measuring with minimum ADC? *AJNR Am J Neuroradiol*. 2012 Oct 18
- Singh P, Tripcony L, Nicklin J. Analysis of prognostic variables, development of predictive models and stratification of risk groups in surgically treated FIGO early-stage (IA-IIA) carcinoma cervix. *Int J Gynecol Cancer*. 2012;22(1):115-22.

# Queensland Haemophilia Centre



**Dr John Rowell**  
Director, Haematology

## Overview

The Queensland Haemophilia Centre is a statewide service based at RBWH. The centre provides comprehensive care for those with haemophilia and other inherited bleeding disorders. Designated staff provide medical, nursing, physiotherapy and social work input into patient care. This includes specialised support including diagnosis, factor replacement therapy, musculo-skeletal and orthopaedic assessment and management, care and support in relation to blood-borne viruses, genetic counselling and psychosocial support.

This year the centre's Physiotherapist commenced a research project aiming to provide practical information for management of joints for individuals with haemophilia. This is a short trial looking at the immediate and short term response to gentle, hands on therapy for haemophilic arthritis in the knee and ankle.

## Research staff

Name	Qualifications	Position	Interests/specialties
Dr John Rowell	MBBS, FRCPA, MBA	Director, Haematology; Pathology Queensland and Queensland Haemophilia Centre, CCS	haemophilia
Beryl Zeissink	RN, MNurs, MSc (GenetCouns)	Clinical Nurse Consultant	haemophilia
Maureen Spilsbury	BSocWk (Hons)	Advanced Social Worker	psychosocial aspects of inherited bleeding disorders
Emma Patterson	BPhys	Advanced Physiotherapist	haemophilia, musculoskeletal physiotherapy

## Research grants

Investigators	Research title	Granting body	Amount awarded	Years of funding
Paterson, E., Rowell, J.	The effects of manual therapy for haemophilic arthritis of the lower limb: A pilot study	Haemophilia Research Fund	\$360	2012-2013

## Publications

Brown SA, Barnes C, Curtin J, Dunkley S, Ockleford P, Rowell J, Smith M, Tran H. How we use recombinant activated factor VII in patients with Haemophilia A or B with inhibitors. Intern Med J. 2012;42(11):1243-50.

# Nursing



**Adj. Assoc. Prof.  
Alanna Geary**  
Nursing Director,  
Cancer Care Services

## Overview

The nursing team comprises 277 nursing staff, providing quality nursing care across the Clinical Haematology and Bone Marrow Transplant Unit, the Department of Medical Oncology, the Department of Radiation Oncology and the Queensland Haemophilia Centre.

The growing demand of cancer care has presented a challenge for the nursing profession in its workload, workforce issues, and most importantly the need to provide innovative and cost-effective nursing care. Cancer nurses play an important and unique role in responding to the needs of people affected by cancer throughout the continuum of care, from prevention to survivorship, end-of-life care and bereavement support.

The nursing research team was established in 2008 with the aim of providing an infrastructure for evidence generation and utilisation to ensure that our nursing care in Cancer Care Services is at the world-class level.

The team is involved in national and international research efforts including a number of National Health and Medical Research Council (NHMRC) funded research projects to examine clinical practices that are important for improving clinical outcomes for people affected by cancer. The research team also works in partnership with the Cochrane Collaboration, Centre for Clinical Nursing, Queensland University of Technology (QUT), Griffith University, and The University of Queensland (UQ).

2013 will see the introduction of the Nursing Professorial Precinct in Cancer Care Services in collaboration with QUT. This precinct will assist in the utilisation of contemporary evidence to further inform sound clinical nursing practice.

## Research staff

Name	Qualifications	Position	Interests/specialties
Raymond Chan	RN, BN, MAppSc (Research), FACN	Nurse Researcher	supportive cancer care, evidence-based practice, symptom management, palliative care, skin toxicity
Jennifer Mann	RN, BN, GradCertMed/ SurgNurs	Clinical Nurse (Research)	radiation-induced skin toxicity
Jessica Kelly	RN, BN	Clinical Nurse (Research)	central venous access devices, infection control

## Supervised post-graduate students

Name	Current studies	Research topic
Chan R	PhD	Self-management associated with fatigue in patients with advanced cancer
Gavin N	PhD	Bacteraemia associated with total parenteral nutrition (TPN) feeding in hospitalised patients
Wong A	PhD	Using information technology to support evidence-based cancer nursing care
O'Dell E	Master of Advanced Practice	The journey of patients with relapsed haematological cancer
Flynn J	Master of Advanced Practice	Sterile vs aseptic non-touch technique for central venous catheters

## Awards and achievements

Award	Event	Name
Editorial Board Member, Cancer Nursing: An International Journal for Cancer Care		Chan, R.

## Research grants

Investigators	Research title	Granting body	Amount awarded	Years of funding
Rickard, C., Wallis, M., Young, J., Gowardman, J., Whitby, M., Chan, R. (AI)	The RSVP Trial: Replacement of Intravascular device administration sets after Standard Versus Prolonged use	NHMRC	\$1,555,305	2011-2014

## Research grants

Investigators	Research title	Granting body	Amount awarded	Years of funding
Mollee, P., Kennedy, G., Looke, D., Van Kulenburg, A., Geary, A.	Catheter-associated bloodstream infections in adults with cancer: A prospective randomised controlled trial	NHMRC/ Queensland Cancer Council	\$262,200.00	2012-2014
Chan, R., Keller, J., Cheuk, R., Tripcony, L., Blades, R., Keogh, S.	A double-blind randomised controlled trial of a natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer	Office of Health and Medical Research, Queensland Health	\$15,000	2012
Chan, R., Keller, J., Cheuk, R., Tripcony, L., Blades, R., Keogh, S.	A double-blind randomised controlled trial of a natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer	RBWH Foundation	\$60,000	2011-2012
Chan, R., Keller, J., Cheuk, R., Tripcony, L., Blades, R., Keogh, S.	A double-blind randomised controlled trial of a natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer	Cancer Nurses Society Australia	\$6,000	2012
Gavin, N., Rickard, C.	Bacteraemia associated with total parenteral nutrition (TPN) feeding in hospitalised patients	Centre of Research Excellence in Nursing, Griffith University	\$96,000	2012-2014

## Publications

Chan R, Webster J, Marquart L. A Systematic Review: Orientation programs for new cancer patients and their carers. *International Journal of Nursing Studies*. 2012;49:1558-1567.

Chan R, Northfield S, Alexander A, Rickard C. Using the collaborative evidence-based practice model: a systematic review and uptake of chlorhexidine-impregnated sponge dressings in a tertiary cancer centre. *Australian Journal of Cancer Nursing*. 2012;13(2):10-15.

Chan R, Larsen E, Chan P. Re-examining the evidence in Radio-dermatitis Management Literature: An overview and critical appraisal of Systematic Reviews. *International Journal of Radiation Oncology Biology Physics*. 2012;84(3):e357-e362.

Chan R, Keller J, Cheuk R, Tripcony L, Blades R, Keogh S. A double-blind randomised controlled trial of a natural oil-based emulsion containing allantoin versus aqueous cream for managing radiation-induced skin reactions in patients with cancer. *Radiation Oncology*. 2012;7(121):1-7.

Chan R, Alexander A, Bransdon M, Webster J, Hughes B, Brown L, Graham T. Challenging the distal-to-proximal technique in the administration of anti-cancer therapies: a prospective cohort study. *Cancer Nursing*. 2012;35(5):E35-40.

Chan R. The two Cs to evidence based infusion nursing: Critical examination and Collaboration. *Journal of Infusion Nursing*. 2012;35(4):208-209.

Chan R, Wong A. Two decades of exceptional achievements: does the evidence support nurses to favour Cochrane systematic reviews over other systematic reviews? *International Journal of Nursing Studies*. 2012;49(7): 773-774.

So W, Chan R, Chan D, Hughes B, Chair SY, Choi KC, Chan C. Quality of life among head and neck cancer survivors at one year after treatment- a systematic review. *European Journal of Cancer*. 2012;48(15):2391-2408.

